Working with the Patient Status Engine and Isansys engineers, hepatologists at the Royal Free Hospital in London, England, developed a new data-driven biomarker that identified patients with advanced cirrhosis of the liver most at risk of decomposition.
The currrent standard procedure to identify liver disease patients most at risk of decomposition is to bring them into the hospital for a blood-based lab test that takes at least a day to run. At the end of the day, depending on the test results, patients are informed as to whether they will need to be admitted or not.
The new biomarker offers several key benefits over the current test:
(a) it requires only 10 - 20 mins of data from the Isansys Lifetouch
(b) the data can be analysed in real time
(c) the data can be collected in the patient's own home
This new biomarker developed with the data from the PSE offers the potential to reduce costs for healthcare providers and inconvenience for these patients through more frequent screening at home, earlier indication of deterioration, and the possibility of a community based intervention to avoid a costly and traumatic hospital admission.
The new biomarker also predicted 90 day mortality in certain patients.
Results of the study will be published in the near future.
Doctors from The Institute for Liver and Digestive Health (University College London)working at the Royal Free Hospital used the data from the Patient Status Engine to develop a new biomarker for determining the status of their patients with advanced liver disease.
“Continuous monitoring of patients with simple information-based technology facilitates early problem recognition and intervention and helps reduce the number of hospital readmissions for advanced liver disease patients and deaths from the disease”
Dr Raj Mookerjee
Royal Free Hospital, London
Outcomes and Learnings from the study at the Royal Free Hospital:
High quality data
Allowed for simpler analysis and less complex more readily validated algorithms
Creation of big new data sets
From patients whose physiological data is not normally collected and analysed in such detail
Data collected anywhere
Patients do not need to be in a clinical setting
Data access and analysis tools provided
A suite of included applications in the PSE simplifies data access and analysis
New digital biomarkers
Point to the future, but require larger data sets, higher resolution data and clinical validation
Accurately synchronised data inputs
A key feature of the PSE that enables the development of new multi-parameter biomarkers
Get in Touch
Get in Touch